Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Mittal

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Breast Cancer Research and Treatment|December 14, 2011
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patientsSarika Jain, Maureen M Ward, Jennifer O'Loughlin, et al.
Research Square|October 4, 2023
Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve checkpoint blockadeGeoffrey J Markowitz, Yi Ban, Diamile A Tavarez, et al.
Nature Communications|December 27, 2022
PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progressionLufei Sui, Suming Wang, Debolina Ganguly, et al.
Nature Communications|January 9, 2023
Tumor-intrinsic IRE1α signaling controls protective immunity in lung cancerMichael J P Crowley, Bhavneet Bhinder, Geoffrey J Markowitz, et al.
Cancer Discovery|October 2, 2025
Epigenetic Regulation of Chromosomal Instability by EZH2 MethyltransferaseYang Bai, Albert S Agustinus, Shira Yomtoubian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2020
Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung MetastasesNancy Chan, Amy Willis, Naomi Kornhauser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung MetastasesNancy Chan, Amy Willis, Naomi Kornhauser, et al.
Nature Communications|January 3, 2024
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trialNasser K Altorki, Zachary H Walsh, Johannes C Melms, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2014
Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signalingBhuvanesh Dave, Sergio Granados-Principal, Rui Zhu, et al.
Nature Communications|December 19, 2023
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trialNasser K Altorki, Zachary H Walsh, Johannes C Melms, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Breast Cancer Research and Treatment|December 14, 2011
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patientsSarika Jain, Maureen M Ward, Jennifer O'Loughlin, et al.
Research Square|October 4, 2023
Deficiency of metabolic regulator PKM2 activates the pentose phosphate pathway and generates TCF1+ progenitor CD8+ T cells to improve checkpoint blockadeGeoffrey J Markowitz, Yi Ban, Diamile A Tavarez, et al.
Nature Communications|December 27, 2022
PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progressionLufei Sui, Suming Wang, Debolina Ganguly, et al.
Nature Communications|January 9, 2023
Tumor-intrinsic IRE1α signaling controls protective immunity in lung cancerMichael J P Crowley, Bhavneet Bhinder, Geoffrey J Markowitz, et al.
Cancer Discovery|October 2, 2025
Epigenetic Regulation of Chromosomal Instability by EZH2 MethyltransferaseYang Bai, Albert S Agustinus, Shira Yomtoubian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2020
Correction: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung MetastasesNancy Chan, Amy Willis, Naomi Kornhauser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung MetastasesNancy Chan, Amy Willis, Naomi Kornhauser, et al.
Nature Communications|January 3, 2024
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trialNasser K Altorki, Zachary H Walsh, Johannes C Melms, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 31, 2014
Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signalingBhuvanesh Dave, Sergio Granados-Principal, Rui Zhu, et al.
Nature Communications|December 19, 2023
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trialNasser K Altorki, Zachary H Walsh, Johannes C Melms, et al.
Pageof 11